Abstract
Etripamil (CARDAMYST[TM]) is an intranasal L-type calcium channel blocker (CCB) developed by Milestone Pharmaceuticals for the treatment of symptomatic paroxysmal supraventricular tachycardia (PSVT) and is under investigation for atrial fibrillation with rapid ventricular rate (AF-RVR). It received its first approval on the 12 December 2025 in the USA for the conversion of acute symptomatic PSVT episodes to sinus rhythm in adults. Additional global regulatory filings of etripamil for PSVT in adults, a phase II trial of etripamil in pediatrics, and a phase III trial for AF-RVR are in progress. This article summarizes the milestones in the development of etripamil leading to this first approval for PSVT.
Pub Type(s)
Journal Article
Language
eng
PubMed ID
42068525
Citation
Brown, Michael B.. "Etripamil: First Approval." Drugs, 2026.
Brown MB. Etripamil: First Approval. Drugs. 2026.
Brown, M. B. (2026). Etripamil: First Approval. Drugs. https://doi.org/10.1007/s40265-026-02321-1
Brown MB. Etripamil: First Approval. Drugs. 2026 May 2; PubMed PMID: 42068525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Etripamil: First Approval.
A1 - Brown,Michael B,
Y1 - 2026/05/02/
PY - 2026/03/30/received
PY - 2026/04/08/accepted
PY - 2026/5/3/medline
PY - 2026/5/3/pubmed
PY - 2026/5/2/entrez
JF - Drugs
JO - Drugs
N2 - Etripamil (CARDAMYST[TM]) is an intranasal L-type calcium channel blocker (CCB) developed by Milestone Pharmaceuticals for the treatment of symptomatic paroxysmal supraventricular tachycardia (PSVT) and is under investigation for atrial fibrillation with rapid ventricular rate (AF-RVR). It received its first approval on the 12 December 2025 in the USA for the conversion of acute symptomatic PSVT episodes to sinus rhythm in adults. Additional global regulatory filings of etripamil for PSVT in adults, a phase II trial of etripamil in pediatrics, and a phase III trial for AF-RVR are in progress. This article summarizes the milestones in the development of etripamil leading to this first approval for PSVT.
SN - 1179-1950
UR - https://www.unboundmedicine.com/prime/citation/42068525/Etripamil:_First_Approval.
DB - PRIME
DP - Unbound Medicine
ER -
